Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CRM197 is a non-toxic mutant of the diphtheria toxin, widely used as a carrier protein in conjugate vaccines to enhance immunogenicity of polysaccharides and haptens. It is produced by a single amino acid substitution (Gly52→Glu), abolishing ADP-ribosylation activity and rendering it non-toxic, while retaining immunological identity to wild-type diphtheria toxin. Used in vaccines against pneumococcal, meningococcal, and Haemophilus influenzae type b diseases.
Acts as a carrier protein; conjugation converts immune response from T-cell independent to T-cell dependent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Diphtheria Toxin Cross-Reactive Material 197 (CRM197).